Brazil Issues Patent To Theratechnologies For Tesamorelin

The Brazil Patent and Trademark Office has issued patent number 9608799-4 to Theratechnologies, entitled ‘Chimeric fatty body-pro-GRF analog with increased biological potency and pharmaceutical formulation’ for its lead-compound, Tesamorelin. The grant of the patent provides protection in Brazil until December 2019.

Theratechnologies has submitted New Drug Application (NDA) to the FDA on May 29, 2009, for Tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.

The FDA has accepted to file the NDA for Tesamorelin on 12 August, 2009. Under the terms of the company’s collaboration and licensing agreement with EMD Serono, the acceptance to file tesamorelin NDA is associated with a milestone payment of $10m.

Yves Rosconi, president and CEO of Theratechnologies, said: “This patent aligns us well in executing one of our top priorities, which is to expand commercialisation into various geographies for Tesamorelin in HIV-associated lipodystrophy.”